BioLife Solutions, Inc. (BLFS) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

18/25

Growth 4 Margin 4 Expansion 4 Platform 3 Financial 3

latest quarter score

Earnings Reports

18
BioLife Solutions (BLFS) Q1 2026: BPM Revenue Jumps 25% as Commercial Therapy Penetration Deepens
June 17, 2026
21
BioLife Solutions (BLFS) Q2 2025: Cell Processing Revenue Up 28% as BPM Share Hits 70% of U.S. CGT Trials
June 16, 2026
19
BioLife Solutions (BLFS) Q3 2025: Cell Processing Revenue Jumps 33% as Pure Play Model Takes Hold
June 16, 2026
19
BioLife Solutions (BLFS) Q4 2025: 29% Revenue Growth Highlights Market Leadership and Margin Expansion
February 26, 2026
23
BioLife Solutions (BLFS) Q1 2025: Cell Processing Revenue Jumps 33% as Commercial Adoption Deepens
July 05, 2025
BioLife Solutions (BLFS) Q3 2024: Cell Processing Revenue Jumps 43% as SciSafe Exit Sharpens Focus
November 12, 2024
BioLife Solutions (BLFS) Q2 2024: Cell Processing Revenue Climbs 11% as Freezer Exit Sharpens Margin Focus
August 08, 2024
BioLife Solutions (BLFS) Q1 2024: GCI Divestiture Drives 13% Pro Forma EBITDA Margin, Refocuses on High-Growth Core
May 09, 2024
BioLife Solutions (BLFS) Q4 2023: Freezer Exit to Lift Margins as Cell Processing Climbs 11% Sequentially
February 29, 2024
11
BioLife Solutions (BLFS) Q3 2023: Cell Processing Down 26% as Freezer Divestiture Nears Completion
November 09, 2023
22
BioLife Solutions (BLFS) Q2 2023: Freezer Divestiture Targets 52% Pro Forma Margin, Refocuses on Core Consumables
August 08, 2023
BioLife Solutions (BLFS) Q1 2023: Freezer Revenue Drops 15% as Portfolio Pivot Accelerates
May 10, 2023

Browse all companies